Oct 22, 6:53 AM ET
Quest Diagnostics said on October 21, 2026 it learned of unauthorized access to its Quanum LSM system, which clients use to place test orders and look up results. The company believes an unauthorized party accessed certain patient records, and the full scope is still under investigation. The company said the incident has not materially disrupted its business operations or its ability to serve patients.
- Unauthorized access to Quanum LSM system discovered October 21, 2026
- Company believes certain patient records were accessed; full scope under investigation
- Federal law enforcement notified and external cybersecurity experts engaged
- Company states business operations and patient service not materially disrupted
Read the filing on SEC.gov ↗
Oct 22, 6:49 AM ET
Quest Diagnostics reported third-quarter 2026 net revenues of $3.10 billion, up 10.0% from a year earlier, with reported diluted EPS of $2.78, up 28.7%, and adjusted diluted EPS of $3.00, up 15.4%. The company raised its full-year 2026 revenue and EPS guidance, which matters to shareholders because the outlook for both revenue and earnings per share moved higher.
- Q3 2026 net revenues of $3,097 million, up 10.0% from $2,816 million in Q3 2025
- Q3 2026 reported diluted EPS of $2.78 vs. $2.16 a year earlier; adjusted diluted EPS of $3.00 vs. $2.60
- Full-year 2026 reported diluted EPS now expected at $10.21 to $10.31, up from $9.97 to $10.17
- Full-year 2026 net revenues now expected at $12.065 billion to $12.105 billion, up from $11.95 billion to $12.05 billion; the company will hold its 2027 Investor Day on March 25, 2027
Read the filing on SEC.gov ↗
Oct 6, 4:30 PM ET
Quest Diagnostics said Catherine T. Doherty will retire in July 2027 and will move to an Executive Vice President role effective November 1, 2026, overseeing health systems, its Corewell Health joint venture, and Project Nova. The filing states her base salary is unchanged at $650,000 and her incentive target remains 80% of base salary, with a new $1.2 million restricted stock unit award planned, so the change is a planned succession transition rather than an abrupt departure.
- Catherine T. Doherty will retire in July 2027 and transition to Executive Vice President effective November 1, 2026.
- Her responsibilities will include health systems, the Corewell Health joint venture, and Project Nova, a multi-year project to modernize Order to Cash business processes.
- The Compensation and Leadership Development Committee approved no change to her $650,000 base salary or 80% incentive target.
- A restricted stock unit award with a target value of $1.2 million has a grant date of November 3, 2026.
Read the filing on SEC.gov ↗
Jul 23, 6:46 AM ET
Quest Diagnostics reported second-quarter 2026 net revenues of $3.04 billion, up 10.2% from a year earlier, and reported diluted EPS of $2.84, up 15.0%. The company raised its full-year 2026 revenue and EPS guidance, which matters to shareholders because it expects higher earnings for the year than it previously forecast.
- Q2 net revenues $3.04 billion, up 10.2%, with 10.0% organic revenue growth
- Q2 reported diluted EPS $2.84, up 15.0%; adjusted diluted EPS $3.12, up 19.1%
- Full-year 2026 revenue guidance raised to $11.95 billion to $12.05 billion from $11.78 billion to $11.90 billion
- Full-year adjusted diluted EPS guidance raised to $11.05 to $11.25 from $10.63 to $10.83; Q2 reported operating margin was 15.1% versus 15.9% a year earlier
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
